FierceBiotech Jan 28, 2026 Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
FierceBiotech Jan 28, 2026 Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
FierceBiotech Jan 28, 2026 Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
FierceBiotech Jan 28, 2026 CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'
FierceBiotech Jan 28, 2026 FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling
FierceBiotech Jan 28, 2026 'We have an expansive view:' Kardigan CEO knits sharper trials, digital health into cardio strategy
FierceBiotech Jan 27, 2026 Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets
FierceBiotech Jan 27, 2026 TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio
FierceBiotech Jan 27, 2026 'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership
FierceBiotech Jan 27, 2026 United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial
FierceBiotech Jan 27, 2026 From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot
FierceBiotech Jan 27, 2026 Lisata reclaims China rights to solid tumor candidate ahead of acquisition
FierceBiotech Jan 27, 2026 After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
FierceBiotech Jan 27, 2026 Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance
FierceBiotech Jan 26, 2026 Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial
FierceBiotech Jan 26, 2026 European investment firm Gimv calls it quits on new life science financing